{"issuance_frequency":"","notes_translated":{"fr":"La présente ligne directrice porte précisément sur les propriétés de résistance à l'altération de produits pharmaceutiques opioïdes à libération contrôlée. Elle est destinée à l'examen préalable à la mise en marché des présentations de drogue, lorsque les promoteurs cherchent à faire approuver des préparations de médicaments opioïdes à libération contrôlée ayant des propriétés de résistance à l'altération et lorsqu'ils souhaitent inclure dans la monographie de produit des énoncés scientifiques et des allégations sur ces propriétés. ","en":"This guidance document is specific to the \"tamper-resistance\" feature of controlled-release opioid products. It is intended for the pre-market review of drug submissions when sponsors seek to obtain approval for controlled-release opioid drug formulations with tamper-resistant properties and wish to include, in product monographs, scientific statements and claims regarding tamper-resistance. "},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"057bdfb2-4a9f-41c2-ada4-4c8bfc450d28","metadata_created":"2021-07-07T19:51:48.544601","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-07T19:51:48.544608","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-07","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Document d'orientation","formulations inviolables","propriétés d'inviolabilité","produits médicamenteux opioïdes","formulations médicamenteuses opioïdes à libération contrôlée","produits opioïdes à libération contrôlée","présentations de drogue","monographies de produits"],"en":["Guidance document","tamper-resistance formulations","tamper-resistant properties","opioid drug products","controlled-release opioid drug formulations","controlled-release opioid products","drug submissions","product monographs"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Ligne directrice : Propriétés de résistance à l'altération de produits pharmaceutiques opioïdes","en":"Guidance Document: Tamper-resistance Formulations of Opioid Drug Products"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"057bdfb2-4a9f-41c2-ada4-4c8bfc450d28","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"52b0e43d-47f2-406d-806e-6dd5dc5c37a0","related_relationship":"","name_translated":{"fr":"Ligne directrice : Propriétés de résistance à l'altération de produits pharmaceutiques opioïdes","en":"Guidance Document: Tamper-resistance Formulations of Opioid Drug Products"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Tamper-resistance Formulations of Opioid Drug Products","language":["en"],"created":"2021-07-07T19:51:48.618423","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/tamper-resistance-formulations-opioid-drug-products.html#a1","last_modified":null,"position":0,"revision_id":"2082df58-1258-41b2-a382-43ab92c271ff","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"057bdfb2-4a9f-41c2-ada4-4c8bfc450d28","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"905c2b27-2c36-41c5-ad42-46d990f572c3","related_relationship":"","name_translated":{"fr":"Ligne directrice : Propriétés de résistance à l'altération de produits pharmaceutiques opioïdes","en":"Guidance Document: Tamper-resistance Formulations of Opioid Drug Products"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Tamper-resistance Formulations of Opioid Drug Products","language":["fr"],"created":"2021-07-07T19:51:48.618429","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/proprietes-resistance-alteration-produits-pharmaceutiques-opioides.html#a1","last_modified":null,"position":1,"revision_id":"2082df58-1258-41b2-a382-43ab92c271ff","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2016-03-30 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"057bdfb2-4a9f-41c2-ada4-4c8bfc450d28","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"This guidance document is specific to the \"tamper-resistance\" feature of controlled-release opioid products. It is intended for the pre-market review of drug submissions when sponsors seek to obtain approval for controlled-release opioid drug formulations with tamper-resistant properties and wish to include, in product monographs, scientific statements and claims regarding tamper-resistance. ","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document: Tamper-resistance Formulations of Opioid Drug Products","revision_id":"2082df58-1258-41b2-a382-43ab92c271ff"}